Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

Roberto Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, S. Amadori

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (

Original languageEnglish
Pages (from-to)1921-1927
Number of pages7
JournalAnnals of Oncology
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Myelodysplastic Syndromes
Quality of Life
Therapeutics
Anemia
Hemoglobins
Multivariate Analysis
Darbepoetin alfa
Neoplasms

Keywords

  • Anemia
  • Darbepoetin alfa
  • Erythropoietin
  • Myelodysplastic syndrome
  • Predictive factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. / Stasi, Roberto; Abruzzese, E.; Lanzetta, G.; Terzoli, E.; Amadori, S.

In: Annals of Oncology, Vol. 16, No. 12, 12.2005, p. 1921-1927.

Research output: Contribution to journalArticle

Stasi, Roberto ; Abruzzese, E. ; Lanzetta, G. ; Terzoli, E. ; Amadori, S. / Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. In: Annals of Oncology. 2005 ; Vol. 16, No. 12. pp. 1921-1927.
@article{2eee58598714437e9490d30bba184b4c,
title = "Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes",
abstract = "Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45{\%}), with 21 major and three minor responses. Most of the responses (21/24; 87.5{\%}) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (",
keywords = "Anemia, Darbepoetin alfa, Erythropoietin, Myelodysplastic syndrome, Predictive factors",
author = "Roberto Stasi and E. Abruzzese and G. Lanzetta and E. Terzoli and S. Amadori",
year = "2005",
month = "12",
doi = "10.1093/annonc/mdi400",
language = "English",
volume = "16",
pages = "1921--1927",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

AU - Stasi, Roberto

AU - Abruzzese, E.

AU - Lanzetta, G.

AU - Terzoli, E.

AU - Amadori, S.

PY - 2005/12

Y1 - 2005/12

N2 - Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (

AB - Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (

KW - Anemia

KW - Darbepoetin alfa

KW - Erythropoietin

KW - Myelodysplastic syndrome

KW - Predictive factors

UR - http://www.scopus.com/inward/record.url?scp=28444489284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444489284&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi400

DO - 10.1093/annonc/mdi400

M3 - Article

VL - 16

SP - 1921

EP - 1927

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -